Accueil>>Signaling Pathways>> Neuroscience>> Neuroendocrinology>>CJC-1295

CJC-1295 (Synonyms: Modified GRF (1-29), CJC-1295-no DAC, GHRH (1-29)-NH2)

Catalog No.GC47097

A synthetic peptide derivative of GHRH

Products are for research use only. Not for human use. We do not sell to patients.

CJC-1295 Chemical Structure

Cas No.: 446036-97-1

Taille Prix Stock Qté
5 mg
43,00 $US
En stock
25 mg
161,00 $US
En stock
50 mg
301,00 $US
En stock
100 mg
556,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CJC-1295 is a synthetic peptide derivative of growth hormone-releasing hormone (GHRH).1 Unlike CJC-1295-DAC, CJC-1295 does not contain a drug affinity complex (DAC) moiety and has a shorter half-life than the DAC-conjugated version in the blood.2 CJC-1295 increases the secretion of growth hormone in primary rat anterior pituitary cells when used from picomolar to micromolar concentrations and into rat blood when administered subcutaneously at a dose of 1 µmol/kg.1

1.Bridon, D.P., Boudjellab, N., Leger, R., et al.Long lasting growth hormone releasing factor derivatives(2002) 2.Teichman, S.L., Neale, A., Lawrence, B., et al.Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJ. Clin. Endocrinol. Metab.91(3)799-805(2006)

Avis

Review for CJC-1295

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CJC-1295

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.